Phacilitate Leaders World

2018 Agenda

2018 Agenda

We’re working hard to finalise the agenda an expert panel for Phacilitate Leaders World 2019. If you’re interested in speaking or would like to submit an abstract please fill in this form and Kim Barnes will be in touch with you soon. In the meantime, you can take a look at last year's agenda below.

Loading
  1. Registration & Buffet Breakfast in the Exhibition Area
  1. 2017: the year everything changed - What do the key events of the past 12 months mean for the future of commercial cell & gene therapy?

  2. 2017: the year everything changed - What do the key events of the past 12 months mean for the future of commercial cell & gene therapy?

  3. 2017: the year everything changed - What do the key events of the past 12 months mean for the future of commercial cell & gene therapy?

  4. 2017: the year everything changed - What do the key events of the past 12 months mean for the future of commercial cell & gene therapy?

  5. 2017: the year everything changed - What do the key events of the past 12 months mean for the future of commercial cell & gene therapy?

  1. Morning Coffee in the Exhibition Area
  1. Reprogramming the tumor microenvironment: conquering immune suppressive molecular pathways

    Emerging Science - Oncology
  2. Reprogramming the tumor microenvironment: conquering immune suppressive molecular pathways

    Emerging Science - Oncology
  3. Reprogramming the tumor microenvironment: conquering immune suppressive molecular pathways

    Emerging Science - Oncology
  4. Reprogramming the tumor microenvironment: conquering immune suppressive molecular pathways

    Emerging Science - Oncology
  5. Reprogramming the tumor microenvironment: conquering immune suppressive molecular pathways

    Emerging Science - Oncology
  6. Reprogramming the tumor microenvironment: conquering immune suppressive molecular pathways

    Emerging Science - Oncology
  7. Reprogramming the tumor microenvironment: conquering immune suppressive molecular pathways

    Emerging Science - Oncology
  1. Facing up to critical raw materials supply shortfalls - the single largest elephant in the commercial cell & gene therapy room?

    Supply Chain - Raw & Starting Materials
  2. Facing up to critical raw materials supply shortfalls - the single largest elephant in the commercial cell & gene therapy room?

    Supply Chain - Raw & Starting Materials
  3. Facing up to critical raw materials supply shortfalls - the single largest elephant in the commercial cell & gene therapy room?

    Supply Chain - Raw & Starting Materials
  1. Buffet Lunch in the Exhibition Area
  1. Engineering the next frontier in cellular immunotherapy: looking beyond CD24

    Emerging Science - Oncology
  2. Engineering the next frontier in cellular immunotherapy: looking beyond CD22

    Emerging Science - Oncology
  3. Engineering the next frontier in cellular immunotherapy: looking beyond CD25

    Emerging Science - Oncology
  4. Engineering the next frontier in cellular immunotherapy: looking beyond CD20

    Emerging Science - Oncology
  5. Engineering the next frontier in cellular immunotherapy: looking beyond CD19

    Emerging Science - Oncology
  6. Engineering the next frontier in cellular immunotherapy: looking beyond CD21

    Emerging Science - Oncology
  7. Engineering the next frontier in cellular immunotherapy: looking beyond CD23

    Emerging Science - Oncology
  1. Starting material optimization for autologous and allogeneic cell & gene therapies

    Supply Chain - Raw & Starting Materials
  2. Starting material optimization for autologous and allogeneic cell & gene therapies

    Supply Chain - Raw & Starting Materials
  3. Starting material optimization for autologous and allogeneic cell & gene therapies

    Supply Chain - Raw & Starting Materials
  4. Starting material optimization for autologous and allogeneic cell & gene therapies

    Supply Chain - Raw & Starting Materials
  1. Afternoon Tea in the Exhibition Area
  1. Securing sufficient manufacturing capacity for a commercializing sector - what are the most viable short- and long-term solutions?

    Cell-based therapy
  2. Securing sufficient manufacturing capacity for a commercializing sector - what are the most viable short- and long-term solutions?

    Cell-based therapy
  1. The promise of bispecific antibodies: the answer to accessing solid tumors?

    Emerging Science - Oncology
  2. The promise of bispecific antibodies: the answer to accessing solid tumors?

    Emerging Science - Oncology
  3. The promise of bispecific antibodies: the answer to accessing solid tumors?

    Emerging Science - Oncology
  4. The promise of bispecific antibodies: the answer to accessing solid tumors?

    Emerging Science - Oncology
  5. The promise of bispecific antibodies: the answer to accessing solid tumors?

    Emerging Science - Oncology
  6. The promise of bispecific antibodies: the answer to accessing solid tumors?

    Emerging Science - Oncology
  7. The promise of bispecific antibodies: the answer to accessing solid tumors?

    Emerging Science - Oncology
  1. Drinks Reception in the Exhibition Area
  1. Registration & Buffet Breakfast in the Exhibition Area
  1. Morning Coffee in the Exhibition Area
  1. Cardiomyocytes, pancreatic islet cells, MSCs… do the latest data support the recent revival in regenerative medicine?

    Emerging Science - Stem cell therapy & tissue engineered products
  2. Cardiomyocytes, pancreatic islet cells, MSCs… do the latest data support the recent revival in regenerative medicine?

    Emerging Science - Stem cell therapy & tissue engineered products
  3. Cardiomyocytes, pancreatic islet cells, MSCs… do the latest data support the recent revival in regenerative medicine?

    Emerging Science - Stem cell therapy & tissue engineered products
  4. Cardiomyocytes, pancreatic islet cells, MSCs… do the latest data support the recent revival in regenerative medicine?

    Emerging Science - Stem cell therapy & tissue engineered products
  5. Cardiomyocytes, pancreatic islet cells, MSCs… do the latest data support the recent revival in regenerative medicine?

    Emerging Science - Stem cell therapy & tissue engineered products
  1. Buffet Lunch in the Exhibition Area
  1. Japan Partnering Lunch

  1. Highlighting and addressing 'critical path' issues in bringing vector manufacturing processes from Phase I/II to commercial scale

    Gene Therapy
  2. Highlighting and addressing 'critical path' issues in bringing vector manufacturing processes from Phase I/II to commercial scale

    Gene Therapy
  3. Highlighting and addressing 'critical path' issues in bringing vector manufacturing processes from Phase I/II to commercial scale

    Gene Therapy
  1. Genetically modified stem cells - hope or hype?

    Emerging Science - Stem cell therapy & tissue engineered products
  2. Genetically modified stem cells - hope or hype?

    Emerging Science - Stem cell therapy & tissue engineered products
  3. Genetically modified stem cells - hope or hype?

    Emerging Science - Stem cell therapy & tissue engineered products
  4. Genetically modified stem cells - hope or hype?

    Emerging Science - Stem cell therapy & tissue engineered products
  5. Genetically modified stem cells - hope or hype?

    Emerging Science - Stem cell therapy & tissue engineered products
  6. Genetically modified stem cells - hope or hype?

    Emerging Science - Stem cell therapy & tissue engineered products
  1. Tour of the Vein-to-Vein Supply Chain Hub

    Supply Chain - Cold chain and data integration/management
  1. Afternoon Tea in the Exhibition Area
  1. Tracking the migration of regenerative medicine to new therapeutic areas and indications

    Emerging Science - Stem cell therapy & tissue engineered products
  2. Tracking the migration of regenerative medicine to new therapeutic areas and indications

    Emerging Science - Stem cell therapy & tissue engineered products
  3. Tracking the migration of regenerative medicine to new therapeutic areas and indications

    Emerging Science - Stem cell therapy & tissue engineered products
  4. Tracking the migration of regenerative medicine to new therapeutic areas and indications

    Emerging Science - Stem cell therapy & tissue engineered products
  5. Tracking the migration of regenerative medicine to new therapeutic areas and indications

    Emerging Science - Stem cell therapy & tissue engineered products
  6. Tracking the migration of regenerative medicine to new therapeutic areas and indications

    Emerging Science - Stem cell therapy & tissue engineered products
  7. Tracking the migration of regenerative medicine to new therapeutic areas and indications

    Emerging Science - Stem cell therapy & tissue engineered products
  1. Supply chain scale up strategies and enabling technologies to minimize CoGs

    Supply Chain - Cold chain and data integration/management
  2. Supply chain scale up strategies and enabling technologies to minimize CoGs

    Supply Chain - Cold chain and data integration/management
  1. Close of Day 2: Evening Boat Party!
  1. Registration & Buffet Breakfast in the Exhibition Area
  1. Finding the perfect balance between regulatory risk and opportunity: vital insights for a globally-minded sector

  2. Finding the perfect balance between regulatory risk and opportunity: vital insights for a globally-minded sector

  3. Finding the perfect balance between regulatory risk and opportunity: vital insights for a globally-minded sector

  4. Finding the perfect balance between regulatory risk and opportunity: vital insights for a globally-minded sector

  1. Morning Coffee in the Exhibition Area
  1. Pointing the way to future R&D success in rare indications

    Emerging Science - Gene therapy for rare diseases
  2. Pointing the way to future R&D success in rare indications

    Emerging Science - Gene therapy for rare diseases
  3. Pointing the way to future R&D success in rare indications

    Emerging Science - Gene therapy for rare diseases
  4. Pointing the way to future R&D success in rare indications

    Emerging Science - Gene therapy for rare diseases
  5. Pointing the way to future R&D success in rare indications

    Emerging Science - Gene therapy for rare diseases
  6. Pointing the way to future R&D success in rare indications

    Emerging Science - Gene therapy for rare diseases
  1. Clinical updates: examining trial designs and the latest data for product candidates based on cord blood and perinatal stem cells

    Cord Blood & Perinatal Stem Cells
  2. Clinical updates: examining trial designs and the latest data for product candidates based on cord blood and perinatal stem cells

    Cord Blood & Perinatal Stem Cells
  3. Clinical updates: examining trial designs and the latest data for product candidates based on cord blood and perinatal stem cells

    Cord Blood & Perinatal Stem Cells
  1. Buffet Lunch in the Exhibition Area
  1. Envisioning the bioprocessing toolbox of the future: proactively planning tomorrow's solutions to meet both manufacturers and tool providers' strategic needs

    Cell-based therapy
  2. Envisioning the bioprocessing toolbox of the future: proactively planning tomorrow's solutions to meet both manufacturers and tool providers' strategic needs

    Cell-based therapy
  1. Pointing the way to future R&D success in rare indications

    Emerging Science - Gene therapy for rare diseases
  2. Pointing the way to future R&D success in rare indications

    Emerging Science - Gene therapy for rare diseases
  3. Pointing the way to future R&D success in rare indications

    Emerging Science - Gene therapy for rare diseases
  4. Pointing the way to future R&D success in rare indications

    Emerging Science - Gene therapy for rare diseases
  5. Pointing the way to future R&D success in rare indications

    Emerging Science - Gene therapy for rare diseases
  1. Clinical updates: examining trial designs and the latest data for product candidates based on cord blood and perinatal stem cells

    Cord Blood & Perinatal Stem Cells
  2. Clinical updates: examining trial designs and the latest data for product candidates based on cord blood and perinatal stem cells

    Cord Blood & Perinatal Stem Cells
  3. Clinical updates: examining trial designs and the latest data for product candidates based on cord blood and perinatal stem cells

    Cord Blood & Perinatal Stem Cells
  1. Afternoon Tea in the Exhibition Area
  1. Close of Phacilitate Cell & Gene Therapy World 2018

 

Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK